[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-promyelocytic-leukemia-with-pml-rara\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-promyelocytic-leukemia-with-pml-rara":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,84,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100631728","phase-3-pivotal-open-label-phase-3-clinical-study-of-qtx-2101-in-adult-patients-with-acute-promyelocytic-leukemia-100631728",false,"NCT07504458","Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia","A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia","QUATRO-APL","Inclusion Criteria:\n\n1. Informed Consent\n2. Participants must be between 18 and under 71 years of age\n3. Participants must have a confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA)\n4. Participants must be classified as low- or intermediate-risk APL\n5. Participants must be willing and able to comply with the scheduled study visits, treatment plans, laboratory tests, contraception guidance, and other procedures\n\nExclusion Criteria\n\n1. Participants who have significant heart rhythm problems including long QT syndrome, serious arrhythmias, very slow heart rate, or prolonged QTc on ECG\n2. Participants who have central nervous system leukemia\n3. Participants having serious ongoing medical conditions or infections including uncontrolled infections, severe organ disease, or conditions that make study participation unsafe\n4. Participants who are pregnant, breastfeeding, or unwilling to use contraception\n5. Participants who are unable to safely take study medication, including severe neuropathy, inability to swallow oral medication, malabsorption issues, or known allergy to ATO or ATRA","ALL","18 Years","71 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.",[28,29,30,31,32],"Acute Promyelocytic Leukemia (APL)","Acute Promyelocytic Leukaemia","Acute Promyelocytic Leukemia With PML-RARA","Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","Acute Promyelocytic Leukemia",[34,32,35,36,37,38,39,40,41,42,43,44,45],"APL","Hematology","Oncology","Leukemia","Hematologic Disease","Drug Therapy","Therapeutics","Blood Cancer","Heme Malignancy","Arsenic","low-risk APL","standard-risk APL","RECRUITING","2026-06-13",{"date":49,"type":50},"2026-06-16","ACTUAL",{"date":52,"type":50},"2026-06-08",{"date":54,"type":22},"2030-12",{"name":56,"class":57},"Quetzal Therapeutics","INDUSTRY",7,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100164100","phase-2-tretinoin-and-arsenic-trioxide-with-or-without-gemtuzumab-ozogamicin-in-treating-patients-with-previously-untreated-acute-promyelocytic-leukemia-100164100","NCT01409161","Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)","Inclusion Criteria:\n\n* A diagnosis of APL based on the presence of the PML-RAR-alpha fusion gene by cytogenetics, polymerase chain reaction (PCR), or POD test\n* Ability to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of the study\n* Patients in whom therapy for APL was initiated on an emergent basis are eligible (patients may have already started treatment with ATRA, ATO, and\u002For one dose of idarubicin due to the urgency to start therapy early)\n* Women of child-bearing potential must have a negative serum pregnancy test at screening; in addition to having a negative pregnancy test confirmed at screening, all female participants of childbearing potential must have a negative pregnancy test confirmed within 48 hours prior to dosing with the study drug\n* All sexually active subjects (males and females of child-bearing potential) agree to use 2 effective methods of contraception for the duration of the study\n\nExclusion Criteria:\n\n* Fridericia corrected QT (QTcF) interval on the electrocardiogram (EKG) greater than 480 milliseconds\n* Patients with creatinine \\> 2.5 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease\n* Patients with total bilirubin \\>= 2.0 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease\n* Patients with alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) \\> 3 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease","10 Years",{"count":68,"type":22},151,[70],"PHASE2","This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as gemtuzumab ozogamicin, may find certain cancer cells and kill them without harming normal cells. Giving tretinoin and arsenic trioxide together with gemtuzumab ozogamicin may kill more cancer cells.",[30],"2026-05-18",{"date":75,"type":50},"2026-05-20",{"date":77,"type":50},"2011-10-05",{"date":79,"type":22},"2027-12-18",{"name":81,"class":82},"M.D. Anderson Cancer Center","OTHER",5,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100239095","phase-1-petmri-18f-fdg-petct-and-whole-body-mri-in-finding-extramedullary-myeloid-leukemia-in-patients-with-newly-diagnosed-acute-myeloid-leukemia-100239095","NCT02390635","PET\u002FMRI, 18F-FDG PET\u002FCT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia","PET\u002FMR, PET\u002FCT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\n* Patients with newly diagnosed AML\n* Non-English speaking subjects will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consenting non-English speaking subjects.\n\nExclusion Criteria:\n\n* Patients with contraindications to MR\n* Patients with a known allergy to MR contrast agents\n* Uncontrollable claustrophobia\n* Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or Cytarabine more than 1 g per square meter.\n* Patients with secondary or relapsed AML or APL should be excluded.\n* Patients with known extramedullary leukemia\n* Positive pregnancy test in a female of childbearing potential\n* Younger than 18 years\n* Greater than 400 pounds in weight\n* Patients with uncontrolled diabetes\n* Cognitive impaired adults or prisoners will be excluded\n* Estimated glomerular filtration rate (eGFR \\\u003C30) will be excluded",{"count":92,"type":22},77,[94],"PHASE1","This pilot phase I trial studies how well positron emission tomography (PET)\u002Fmagnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET\u002Fcomputed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET\u002FMRI, 18F-FDG PET\u002FCT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.",[97,30],"Acute Myeloid Leukemia","2026-04-14",{"date":100,"type":50},"2026-04-17",{"date":102,"type":50},"2020-07-15",{"date":104,"type":22},"2027-09-15",{"name":81,"class":82},1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100615733","phase-3-a-trial-to-investigate-whether-oral-arsenic-trioxide-is-similar-to-intravenous-arsenic-trioxide-in-pharmacokinetics-safety-and-efficacy-latitudesdkars-301-100615733","NCT07296445","A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE\u002FSDKARS-301)","LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia","LATITUDE","Key Inclusion Criteria:\n\n* Participants must have diagnosis of newly diagnosed non-high risk APL with a WBC count at diagnosis ≤ 10,000 cells\u002FµL, completed induction with ATO\u002FATRA and achieved morphologic CR with hematologic recovery\n* Eastern Cooperative Oncology Group performance status ≤2\n* Adequate liver, kidney, and cardiac function\n* Have a life expectancy of at least 9 months\n* Negative serum pregnancy test\n\nKey Exclusion Criteria:\n\n* Diagnosis of relapsed or refractory APL.\n* Fridericia's corrected QT interval (QTcF) \\>450 milliseconds (males) and \\>460 milliseconds (females)\n* Any gastrointestinal (GI) issue likely to affect oral drug absorption\u002Fmetabolism or inability to swallow oral medication\n* Prior malignancy or currently receiving treatment for a non-APL malignancy, with the following exceptions: basal cell or squamous cell skin cancer treated with surgical resection, in situ cervical cancer, localized prostate cancer or breast cancer treated with hormone therapy or surgical resection, or other cancer from which the participant has been disease free for at least 2 years.\n* Pregnant or nursing females or is of reproductive potential and unwilling to comply with contraceptive requirements.\n* Participant has known active or chronic hepatitis B or active hepatitis C (HCV) infection or human immunodeficiency virus (HIV)-positive with detectable viral load.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.","12 Years",{"count":117,"type":22},120,[25],"LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk, Acute Promyelocytic Leukemia\n\nRationale:\n\nSDK Therapeutics is developing an oral formulation of arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL). Patients with APL are usually treated with arsenic trioxide (ATO) through an IV along with all-trans retinoic acid (ATRA) taken by mouth. Receiving ATO through an IV requires patients with APL to go to the hospital a lot and get long treatments (sometimes every day over a year of treatment). This can be hard and uncomfortable. If ATO can be taken by mouth, it would be much easier for patients and their families.\n\nObjective:\n\nThe main objective is to show that the body absorbs the same amount of ATO whether it's taken by mouth or through an IV. Other objectives include checking if ATO taken by mouth works just as well, causes fewer heart problems, is safe, and improves quality of life compared with ATO given through an IV.\n\nMain trial endpoints:\n\nThe main endpoint being measured is how much ATO is in the blood after 5 doses. Another important endpoint is how many patients have no signs of cancer in their blood after 3 rounds of treatment.\n\nSecondary trial endpoints:\n\nOther things being measured include: whether patients stay cancer-free over 2 years; changes in heart rhythm; side effects and lab test results; how patients feel during treatment; how much of ATO is in the blood; and how often patients feel bothered by side effects.\n\nTrial design:\n\nThis is an open-label study, meaning everyone knows which treatment they are getting. Patients will get 4 rounds of treatment, each lasting 8 weeks. After that, patients will have check-ups every 3 months to assess safety and disease status for a total of 2 years.\n\nTrial population:\n\nThe study includes adults and teens (12 years and older) who have APL, are not high-risk, and have already finished the first part of their treatment (induction) with IV ATO and ATRA.\n\nInterventions:\n\nThere are 3 groups in the study:\n\nCohort A: Takes 0.15 mg\u002Fkg Oral ATO for 3 rounds, then switches to 0.15 mg\u002Fkg IV ATO for part of the 4th round.\n\nCohort B: Takes 0.15 mg\u002Fkg IV ATO for 3 rounds, then switches to 0.15 mg\u002Fkg Oral ATO for part of the 4th round.\n\nCohort C: Takes 0.15 mg\u002Fkg Oral ATO for all 4 rounds.\n\nAll cohorts also take 45 mg\u002Fm2\u002Fday ATRA during certain weeks of each round. Doctors will assess efficacy by checking bone marrow samples before and during treatment to see if the cancer is gone. Special lab tests will be used to look for cancer cells. Safety will be assessed by checking for side effects using blood tests, heart tests, physical exams, and other health checks. Quality of life will be assessed by the patients who will fill out surveys about how they feel during treatment and how much the side effects bother them. The study will also look at how often patients need to go to the doctor or hospital; how treatment affects daily life and work; and how satisfied patients are with their treatment.",[28,29,30,31,34,32,121,122,123],"Leukaemia","Leukemia Acute Promyelocytic Leukemia (APL)","Leukemia, Acute",[125,126],"Oral Arsenic Trioxide","Oral ATO","NOT_YET_RECRUITING","2025-12-25",{"date":130,"type":50},"2025-12-29",{"date":132,"type":22},"2026-01",{"date":134,"type":22},"2029-01",{"name":136,"class":57},"SDK Therapeutics, Inc."]